Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE768.45-9.75 (-1.25 % )
PREV CLOSE (Rs.) 778.20
OPEN PRICE (Rs.) 789.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 5280
TODAY'S LOW / HIGH (Rs.)766.00 789.50
52 WK LOW / HIGH (Rs.)470 818.6
NSE767.65 -11.5 (-1.48 % )
PREV CLOSE(Rs.) 779.15
OPEN PRICE (Rs.) 779.15
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 767.65 (414 )
VOLUME 71724
TODAY'S LOW / HIGH(Rs.) 765.00 785.90
52 WK LOW / HIGH (Rs.)470 819.7

Company News

Date Heading Details
29-Jul-2021 Announcement Under Regulation 30 ( LODR) - DIVIDEND UPDATE Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., July 29, 2021 inter alia, duly approved / took on record the following: ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended June 30, 2021; ? Convening of Annual General Meeting (AGM) of the Members of the Company on Wednesday, September 01, 2021. ? Declaration of interim dividend of Rs. 6.01 (at the rate of 601%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2021-2022; ? Further, as Communicated in our intimation letter dated July 26, 2021, the record date for determining the eligibility of shareholders for payment of interim dividend has been fixed as August 6, 2021. The payment of interim dividend would be made to the eligible shareholders on or before August 28, 2021.
29-Jul-2021 Board Meeting Outcome for SUBJECT ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended June 30, 2021; ? Convening of Annual General Meeting (AGM) of the Members of the Company on Wednesday, September 01, 2021. ? Declaration of interim dividend of Rs. 6.01 (at the rate of 601%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2021-2022; ? Further, as Communicated in our intimation letter dated July 26, 2021, the record date for determining the eligibility of shareholders for payment of interim dividend has been fixed as August 6, 2021. The payment of interim dividend would be made to the eligible shareholders on or before August 28, 2021.
29-Jul-2021 Board Meeting Outcome for SUBJECT ? Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended June 30, 2021; ? Convening of Annual General Meeting (AGM) of the Members of the Company on Wednesday, September 01, 2021. ? Declaration of interim dividend of Rs. 6.01 (at the rate of 601%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2021-2022; ? Further, as Communicated in our intimation letter dated July 26, 2021, the record date for determining the eligibility of shareholders for payment of interim dividend has been fixed as August 6, 2021. The payment of interim dividend would be made to the eligible shareholders on or before August 28, 2021.
26-Jul-2021 Eris Lifesciences informs about board meeting to consider interim dividend <p align="justify">Eris Lifesciences has informed that the board of directors shall consider the declaration of interim dividend for the financial year 2021-22 at its meeting which is scheduled to be held on 29th July 2021. In the event of declaration of interim dividend as aforesaid, the proposed record date for the purpose of determining the members eligible for receiving the said interim dividend shall be 6th August, 2021.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
26-Jul-2021 Board to consider Interim Dividend Eris Lifesciences Ltd has informed BSE that the board of directors shall consider the declaration of interim dividend for the financial year 2021-22 at its meeting which is scheduled to be held on July 29, 2021.
22-Jul-2021 Board Meeting Intimation for Board Meeting Intimation Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2021 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on Thursday, 29th July, 2021 to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30th June, 2021.
21-Jul-2021 Eris Lifesciences informs about board meeting <p align="justify">Eris Lifesciences has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Thursday, 29th July, 2021 to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended 30th June, 2021. Further, as informed by them through letter dated 24th June, 2021, the trading window has been already closed from 1st July, 2021 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on ‘Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company for the purpose of Board Meeting.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
13-Jul-2021 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of 82,841 equity shares pursuant to ESOP-2017 Scheme
06-Jul-2021 Eris Lifesciences informs about analyst meet <div align="justify"><span>In accordance with the requirements of Regulation 30 and other applicable Regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015, Eris Lifesciences has informed that it enclosed the schedule of Analyst/ Institutional Investor Meeting to be held on Tuesday, 6th July, 2021.</span></div><font face="sans-serif"><span><div align="justify"><br></div></span></font><div align="justify"><font face="sans-serif"><span>The above information is a part of company's filings submitted to BSE.</span></font></div><div><br></div>
02-Jul-2021 Announcement Under Regulation 30(LODR) Sub Regulation 10 - Clarification On Increase In Volume Subject: Clarification on Increase in Volume Ref. No.: NSE/CM/Surveillance/10927 Dear Sir / Madam, With reference to the above mentioned letter, we would like to inform that there is no such announcement or price sensitive information, which is pending to be intimated by the Company to the stock exchanges concerning its performance/ operations. We wish to reiterate and clarify that all the latest relevant information about the Company, which in our opinion may have a bearing on the price / volume behaviour in the scrip has already been disclosed to the Exchanges. Further, the Company is in compliance with the SEBI (Listing Obligations and disclosures Requirements) Regulations and shall keep the stock exchanges duly informed of all the price sensitive information(s) in future as well.